The H3.3K27M mutation is found in the vast majority of diffuse midline glioma and is not a suitable target for cancer immunotherapy, most likely due to insufficient epitope processing and/or amount to be recognized by HLA-A restricted CD8+ T cells [54]. The gene discussed is CD8A; the disease is cancer.